

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 May 2005 (12.05.2005)



PCT

(10) International Publication Number
WO 2005/041899 A2

- (51) International Patent Classification⁷: **A61K** (74) Agent: SPARKS, Rodney, L.; University of Virginia Patent Foundation, 1224 West Main Street, Suite 1-110, Charlottesville, VA 22903 (US).
- (21) International Application Number:
PCT/US2004/036563
- (22) International Filing Date:
3 November 2004 (03.11.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/516,887 3 November 2003 (03.11.2003) US
- (71) Applicant (for all designated States except US): UNIVERSITY OF VIRGINIA PATENT FOUNDATION [US/US]; 1224 West Main Street, Suite 1-110, Charlottesville, VA 22903 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LYNCH, Kevin, R. [US/US]; 1632 Meadowbrook Heights Road, Charlottesville, VA 22901 (US). MACDONALD, Timothy, L. [US/US]; 2 Ivy Depot Lane, Ivy, VA 22945 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ORALLY AVAILABLE SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS AND ANTAGONISTS



(57) Abstract: The present invention relates to S1P analogs that have activity as S1Preceptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R₁₁ is C₅-C₁₈ alkyl or C₅-C₁₈ alkenyl; Q is selected from the group consisting of C₃-C₆ optionally substituted cycloalkyl, C₃-C₆ optionally substituted heterocyclic, C₃-C₆ optionally substituted aryl C₃-C₆ optionally substituted heteroaryl and; R₂ is selected from the group consisting of H, C₁-C₄ alkyl, (C₁-C₄ alkyl)OH and (C₁-C₄ alkyl)NH₂; R₂₃ is H or C₁-C₄ alkyl, and R₁₅ is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.



Published:

— *without international search report and to be republished
upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.